The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism

Chest

Volumn 124, Issue 3 SUPPL., 2003, Pages 40S-48S

  Heit, John A ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Deep vein thrombosis; Prophylaxis; Pulmonary embolism; Thrombin venous thromboembolism; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; BENZAMIDINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; MELAGATRAN; TAMOXIFEN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTIFICIAL HEART PACEMAKER; BLEEDING; BODY MASS; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ELECTRON MICROSCOPY; FRACTURE; GENERAL SURGERY; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; IMMOBILIZATION; INCIDENCE; INJURY; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; PARESIS; PATHOGENESIS; PERIPHERAL VEIN; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SIDE EFFECT; THROMBOCYTE ADHESION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS;

EID: 0141819116     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.3_suppl.40S     Document Type: Article

References (64)

1. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158:585-593
2. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159:445-453
3. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7
4. Mohr DN, Silverstein MD, Heit JA, et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. Mayo Clin Proc 2000; 75: 1249-1256
5. Bergqvist D, Jendteg S, Johansen L, et al. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 1997; 126:454-457
6. Heit JA, Melton LJ III, Lohse CM, et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001; 76:1102-1110
7. Madhok R, Lewallen DG, Wallrichs SL, et al. Trends in the utilization of primary total hip arthroplasty, 1969 through 1990: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 1993; 68:11-18
8. Anderson FAJ, Wheeler HB, Goldberg RJ, et al. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115:591-595
9. Bratzler DW, Raskob GE, Murray CK, et al. Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med 1998; 158:1909-1912
10. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160:809-815
11. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160:3415-3420
12. Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998; 128:467-477
13. Devor M, Barrett-Connor E, Renvall M, et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92:275-282
14. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162:1245-1248
15. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160:761-768
16. Heit JA, Farmer SA, Petterson TM, et al. Venous thromboembolism event type (PE±DVT vs. DVT alone) predicts recurrence type and survival [abstract]. Blood 2002; 100:149a
17. Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326:1240-1245
18. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339:441-445
19. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336:393-398
20. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901-907
21. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332:1661-1665
22. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy: Duration of Anticoagulation Study Group. Am J Med 1998; 104:332-338
23. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801-806
24. Stewart GJ, Ritchie WG, Lynch PR. Venous endothelial damage produced by massive sticking and emigration of leukocytes. Am J Pathol 1974; 74:507-532
25. Samuels PB, Webster DR. The role of venous endothelium in the inception of thrombosis. Ann Surg 1952; 136:422-438
26. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119:132S-175S
27. Nemerson Y. Tissue factor and the initiation of blood coagulation. Adv Exp Med Biol 1987; 214:83-94
28. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999; 96:2311-2315
29. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104:74-78
30. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235:1348-1352
31. Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987; 317:940-945
32. Houghton GR, Papadakis EG, Rizza CR. Changes in blood coagulation during total hip replacement. Lancet 1978; 1:1336-1338
33. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75:818-824
34. Eriksson BI, Eriksson E, Gyzander E, et al. Thrombosis after hip replacement: relationship to the fibrinolytic system. Acta Orthop Scand 1989; 60:159-163
35. Gitel SN, Salvati EA, Wessler S, et al. The effect of total hip replacement and general surgery on antithrombin III in relation to venous thrombosis. J Bone Joint Surg Am 1979; 61:653-656
36. Bevilacqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986; 83:4533-4537
37. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73:159-165
38. Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell 1990; 62:3-6
39. Stewart GJ. Neutrophils and deep venous thrombosis. Haemostasis 1993; 23(suppl 1):127-140
40. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119:176S-193S
41. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29:7095-7101
42. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Haemost 1997; 23:503-516
43. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101:171-181
44. Hopfner R. Ximelagatran (AstraZeneca). Curr Opin Investig Drugs 2002; 3:246-251
45. Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45:1757-1766
46. Stangier J, Rathgen K, Gansser D, et al. Pharmacokinetics of BIBR 953 ZW, a novel low molecular weight direct thrombin inhibitor, in healthy volunteers [abstract]. Thromb Haemost 2001; (suppl)OC2347
47. Stassen JM, Rathgen K, Zimmerman R, et al. Pharmacodynamics of the synthetic direct thrombin inhibitor BIBR953ZW in healthy subjects [abstract]. Thromb Haemost 2001; (suppl)OC 160
48. Eriksson BI, Ekman S, Kalebo P, et al. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996; 347:635-639
49. Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997; 79:326-333
50. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337:1329-1335
51. Ginsberg JS, Nurmohamed MT, Gent M, et al. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994; 90:2385-2389
52. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161:2215-2221
53. Colwell CW, Berkowitz SD, Davidson BL, et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and enoxaparin to prevent venous thromboembolism after total hip replacement [abstract 2952]. Blood 2001; 98:706a
54. Eriksson BI, Arfwiddsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002; 87: 231-237
55. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360:1441-1447
56. Eriksson BI, Agnelli GA, Cohen AT, et al. The oral direct thrombin inhibitor ximelagatran and its subcutaneous (sc) form melagatran, compared to enoxaparin for prophylaxis of venous thromboembolism in total hip or total knee replacement [abstract]. Blood. 2002; 100:82a
57. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002; 137:648-655
58. Francis CW, Berkowitz SD, Comp PC, et al. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR) [abstract]. Blood 2002; 100:82a
59. Eriksson BI, Dahl O, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, BIBR 1048, in patients undergoing total hip replacement [abstract]. Pathophysiol Haemost Thromb 2002; 32(suppl 2):69
60. Schiele F, Lindgaerde F, Eriksson H, et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial; International Multicentre Hirudin Study Group. Thromb Haemost 1997; 77:834-838
61. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99:73-80
62. Eriksson H, Wahlander K, Gustafsson D, et al. A randomized controlled dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1:41-47
63. Wahlander K, Lapidus L, Olsson CG, et al. THRIVE IV: an open-label, pilot study of the treatment of pulmonary embolism with the oral direct thrombin inhibitor ximelagatran [abstract]. Blood 2001; 98:268a
64. Eriksson H, Wahlander K, Lundstrom B, et al. Extended secondary prophylaxis with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial [abstract]. Blood 2002; 100:81a